The unabated synthesis of new nucleoside analogues with antiviral potential: A tribute to Morris J. Robins

Nucleosides, Nucleotides and Nucleic Acids

Volumn 28, Issue 5-7, 2009, Pages 586-600

  De Clercq, Erik ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; PYRIMIDINE NUCLEOSIDE;

ANIMAL; CHEMISTRY; DRUG EFFECT; HUMAN; REVIEW; SYNTHESIS; VIRUS; VIRUS INFECTION;

ANIMALS; ANTIVIRAL AGENTS; HUMANS; PYRIMIDINE NUCLEOSIDES; VIRUS DISEASES; VIRUSES;

EID: 77952302510     PISSN: 15257770     EISSN: 15322335     Source Type: Journal    
DOI: 10.1080/15257770903054159     Document Type: Article

References (47)

1. Robins, M.J.; Nowak, I.; Rajwanshi, V.K.; Miranda, K.; Cannon, J.F.; et al. Synthesis and antiviral evaluation of 6-(alkyl-heteroaryl)furo[2,3-d]pyrimidin-2(3H)-one nucleosides and analogues with ethynyl, ethenyl, and ethyl spacers at C6 of the furopyrimidine core. J. Med. Chem. 2007, 50, 3897–3905.
2. De Clercq, E.; Descamps, J.; Balzarini, J.; Giziewicz, J.; Barr, P.J.; Robins, M.J. Nucleic acid related compounds. 40. Synthesis and biological activities of 5-alkynyluracil nucleosides. J. Med. Chem. 1983, 26, 661–666.
3. ′-deoxyuridine: a potent and selective anti-herpes agent. Proc. Natl. Acad. Sci. USA 1979, 76, 2947– 2951.
4. ′-deoxyuridine in severe herpes zoster. Br. Med. J. 1980, 281, 1178.
5. De Clercq, E. The discovery of antiviral agents: ten different compounds, ten different stories. Med. Res. Rev. 2008, 28, 929–953.
6. Robins, M.J.; Barr, P.J. Nucleic acid related compounds. 31. Smooth and efficient palladium-copper catalyzed coupling of terminal alkynes with 5-iodouracil nucleosides. Tetrahedron Lett. 1981, 22, 421–424.
7. Robins, M.J.; Barr, P.J. Nucleic acid related compounds. 39. Efficient conversion of 5-iodo to 5-alkynyl and derived 5-substituted uracil bases and nucleosides. J. Org. Chem. 1983, 48, 1854–1862.
8. Robins, M.J.; Vinayak, R.S.; Wood, S.G. Solvent, not palladium oxidation state, is the primary determinant for successful coupling of terminal alkynes with iodo-nucleosides. Tetrahedron Lett. 1990, 31, 3731–3734.
9. Crisp, G.T.; Flynn, B.L. Palladium-catalyzed coupling of terminal alkynes with 5-(trifluoromethanesulfonyloxy)pyrimidine nucleosides. J. Org. Chem. 1992, 58, 6614–6619.
10. ′-deoxyuridines and related analogues. J. Heterocyclic Chem. 1991, 28, 1917–1925.
11. ′-deoxyuridine. Can. J. Chem. 1996, 74, 1609–1615.
12. ′-deoxyuridines. Methods Find. Exp. Clin. Pharmacol. 1980, 2, 253–267.
13. De Clercq, E.; Descamps, J.; Verhelst, G.; Walker, R.T.; Jones, A.S.; et al. Comparative efficacy of antiherpes drugs against different strains of herpes simplex virus. J. Infect. Dis. 1980, 141, 563–574.
14. De Clercq, E. Biochemical aspects of the selective antiherpes activity of nucleoside analogues. Biochem. Pharmacol. 1984, 33, 2159–2169.
15. McGuigan, C.; Yarnold, C.J.; Jones, G.; Velázquez, S.; Barucki, H.; et al. Potent and selective inhibition of varicella-zoster virus (VZV) by nucleoside analogues with an unusual bicyclic base. J. Med. Chem. 1999, 42, 4479–4484.
16. McGuigan, C.; Barucki, H.; Blewett, S.; Carangio, A.; Erichsen, J.T.; et al. Highly potent and selective inhibition of varicella-zoster virus by bicyclic furopyrimidine nucleosides bearing an aryl side chain. J. Med. Chem. 2000, 43, 4993–4997.
17. De Clercq, E. Highly potent and selective inhibition of varicella-zoster virus replication by bicyclic furo[2,3-d]pyrimidine nucleoside analogues. Med. Res. Rev. 2003, 23, 253–274.
18. Robins, M.J.; Hatfield, P.W.; Balzarini, J.; De Clercq, E. Nucleic acid related compounds. 47. Synthesis and biological activities of pyrimidine and purine “acyclic” nucleoside analogues. J. Med. Chem. 1984, 27, 1486–1492.
19. Baba, M.; Tanaka, H.; De Clercq, E.; Pauwels, R.; Balzarini, J.; et al. Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative. Biochem. Biophys. Res. Commun. 1989, 165, 1375–1381.
20. Miyasaka, T.; Tanaka, H.; Baba, M.; Hayakawa, H.; Walker, R.T.; et al. A novel lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine. J. Med. Chem. 1989, 32, 2507–2509.
21. De Clercq, E.; Bernaerts, R.; Bergstrom, D.E.; Robins, M.J.; Montgomery, J.A., Holý, A. Antirhi-novirus activity of purine nucleoside analogs. Antimicrob. Agents Chemother. 1986, 29, 482–487.
22. De Clercq, E.; Balzarini, J.; Madej, D.; Hansske, F.; Robins, M.J. Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin. J. Med. Chem. 1987, 30, 481–486.
23. De Clercq, E.; Robins, M.J. Xylotubercidin against herpes simplex virus type 2 in mice. Antimicrob. Agents Chemother. 1986, 30, 719–724.
24. ′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc. Natl. Acad. Sci. USA 1985, 82, 7096–7100.
25. ′-dideoxynucleosides. Proc. Natl. Acad. Sci. USA 1986, 83, 1911–1915.
26. ′-dideoxyriboside of 2,6-diaminopurine selectively inhibits human immunodeficiency virus (HIV) replication in vitro. Biochem. Biophys. Res. Commun. 1987, 145, 269–276.
27. ′-dideoxyriboside. Biochem. Pharmacol. 1988, 37, 1317–1325.
28. ′-dideoxyguanosine against human immunodeficiency virus. Mol. Pharmacol. 1988, 33, 243–249.
29. ′-dideoxyadenosine, an inhibitor of human immunodeficiency virus (HIV) replication. Biochem. Biophys. Res. Commun. 1987, 145, 277–283.
30. ′-dideoxy-2,6-diaminopurine riboside. J. Acquir. Immune Defic. Syndr. 1990, 3, 1140–1147.
31. ′-dideoxy-2,6-diaminopurine ribosides. J. Med. Chem. 1989, 32, 1763–1768.
32. De Clercq, E.; Descamps, J.; De Somer, P.; Holý, A. (S)-9-(2,3-Dihydroxypropyl)adenine: an aliphatic nucleoside analog with broad-spectrum antiviral activity. Science 1978, 200, 563–565.
33. De Clercq, E. S-adenosylhomocysteine hydrolase inhibitors as broad-spectrum antiviral agents. Biochem. Pharmacol. 1987, 36, 2567–2575.
34. De Clercq, E. Antivirals and antiviral strategies. Nature Rev. Microbiol. 2004, 2, 704–720.
35. De Clercq, E. Another ten stories in antiviral drug discovery (part C): “old” and “new” antivirals, strategies and perspectives. Med. Res. Rev. 2009.
36. ′ )-methylenenucleoside analogues that function as mechanism-based inhibitors of S-adenosyl-L-homocysteine hydrolase and/or ribonucleotide reductase. J. Med. Chem. 1992, 35, 2283–2293.
37. ′-(E and Z)-halohomovinyl derivatives of adenosine, inactivation of S-adenosyl-L-homocysteine hydrolase, and correlation of anticancer and antiviral potencies with enzyme inhibition. J. Med. Chem. 1994, 37, 3579–3587.
38. ′-carboxaldehydes and oximes synthesized from adenosine and sugar-modified analogues. J. Med. Chem. 1997, 40, 1608–1618.
39. ′-haloacetylene analogues derived from adenosine). J. Med. Chem. 1998, 41, 3857–3864.
40. Wnuk, S.F.; Mao, Y.; Yuan, C.S.; Borchardt, R.T.; Andrei, G.; Balzarini, J.; De Clercq, E.; Robins, M.J. Discovery of type II (covalent) inactivation of S-adenosyl-L-homocysteine hydrolase involving its “hydrolytic activity”: synthesis and evaluation of dihalohomovinyl nucleoside analogues derived from adenosine. J. Med. Chem. 1998, 41, 3078–3083.
41. Wnuk, S.F.; Valdez, C.A.; Khan, J.; Moutinho, P.; Robins, M.J.; Yang, X.; Borchardt, R.T.; Balzarini, J.; De Clercq, E. Doubly homologated dihalovinyl and acetylene analogues of adenosine: synthesis, interaction with S-adenosyl-L-homocysteine hydrolase, and antiviral and cytostatic effects. J. Med. Chem. 2000, 43, 1180–1186.
42. Janeba, Z.; Balzarini, J.; Andrei, G.; Snoeck, R.; De Clercq, E.; Robins, M.J. Synthesis and biological evaluation of acyclic 3-[(2-hydroxyethoxy)methyl] analogues of antiviral furo-and pyrrolo[2,3-d]pyrimidine nucleosides. J. Med. Chem. 2005, 48, 4690–4696.
43. Robins, M.J.; Miranda, K.; Rajwanshi, V.K.; Peterson, M.A.; Andrei, G.; Snoeck, R.; De Clercq, E.; Balzarini, J. Synthesis and biological evaluation of 6-(alkyn-1-yl)furo[2,3-d]pyrimidin-2(3H)-one base and nucleoside derivatives. J. Med. Chem. 2006, 49, 391–398.
44. Janeba, Z.; Balzarini, J.; Andrei, G.; Snoeck, R.; De Clercq, E.; Robins, M.J. Synthesis and biological evaluation of 5-(alkyn-1-yl)-1-(p-toluenesulfonyl)uracil derivatives. Can. J. Chem. 2006, 84, 580–586.
45. Andrei, G.; Sienaert, R.; McGuigan, C.; De Clercq, E.; Balzarini, J.; Snoeck, R. Susceptibilities of several clinical varicella-zoster virus (VZV) isolates and drug-resistant VZV strains to bicyclic furano pyrimidine nucleosides. Antimicrob. Agents Chemother. 2005, 49, 1081–1086.
46. McGuigan, C.; Pathirana, R.N.; Migliore, M.; Adak, R.; Luoni, G.; Jones, A.T.; Diez-Torrubia, A.; Camarasa, M.-J.; Velázquez, S.; Henson, G.; Verbeken, E.; Sienaert, R.; Naesens, L.; Snoeck, R.; Andrei, G.; Balzarini, J. Preclinical development of bicyclic nucleoside analogues as potent and selective inhibitors of varicella zoster virus. J. Antimicrob. Chemother. 2007, 60, 1316–1330.
47. Canas, S.M.; Wargin, B.; Boehlecke, B.; Henson, G.; Patti, J.M.; Morris, A.M. A single accelerating dose study to evaluate safety and pharmacokinetics (PK) of FV-100 in healthy subjects. Abstracts of the Twenty-First International Conference on Antiviral Research, Montreal, Quebec, Canada, 13–17 April 2008. Antiviral Res. 2008, 78, A32.